• Qian He, Qunying Mao, Chaoqiang An, Jialu Zhang, Fan Gao, Lianlian Bian, Changgui Li, Zhenglun Liang, Miao Xu, and Junzhi Wang.
• National Institutes for Food and Drug Control, Beijing, People's Republic of China.
• Emerg Microbes Infect. 2021 Dec 1; 10 (1): 629-637.

AbstractCOVID-19 vaccines emerging from different platforms differ in efficacy, duration of protection, and side effects. To maximize the benefits of vaccination, we explored the utility of employing a heterologous prime-boost strategy in which different combinations of the four types of leading COVID-19 vaccine candidates that are undergoing clinical trials in China were tested in a mouse model. Our results showed that sequential immunization with adenovirus vectored vaccine followed by inactivated/recombinant subunit/mRNA vaccine administration specifically increased levels of neutralizing antibodies and promoted the modulation of antibody responses to predominantly neutralizing antibodies. Moreover, a heterologous prime-boost regimen with an adenovirus vector vaccine also improved Th1-biased T cell responses. Our results provide new ideas for the development and application of COVID-19 vaccines to control the SARS-CoV-2 pandemic.

39 keywords...

hide…